{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T18:25:04Z","timestamp":1775067904791,"version":"3.50.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:00:00Z","timestamp":1574899200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:00:00Z","timestamp":1574899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s10067-019-04833-6","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T14:42:17Z","timestamp":1576507337000},"page":"613-614","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Symptomatic elevation creatine kinase following treatment of rheumatoid arthritis with baricitinib"],"prefix":"10.1007","volume":"39","author":[{"given":"Pamela","family":"Anjara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maninder","family":"Mundae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,28]]},"reference":[{"key":"4833_CR1","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2147\/TCRM.S192440","volume":"15","author":"P Kawalec","year":"2019","unstructured":"Kawalec P, Sladowska K, Malinowska-Lipien I, Brzostek T, Kozka M (2019) New alternative in the treatment of rheumatoid arthritis: clinical utility of baricitinib. Ther Clin Risk Manag 15:275\u2013284","journal-title":"Ther Clin Risk Manag"},{"issue":"12","key":"4833_CR2","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1002\/jcph.354","volume":"54","author":"JG Shi","year":"2014","unstructured":"Shi JG, Chen X, Lee F, Emm T, Scherle PA, Lo Y, Punwani N, Williams WV, Yeleswaram S (2014) The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1\/2 inhibitor, in healthy volunteers. J Clin Pharmacol 54(12):1354\u20131361","journal-title":"J Clin Pharmacol"},{"issue":"13","key":"4833_CR3","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","volume":"374","author":"MC Genovese","year":"2016","unstructured":"Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, Beattie SD, Koch AE, Cardillo TE, Rooney TP, Macias WL, de Bono S, Schlichting DE, Smolen JS (2016) Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 374(13):1243\u20131252","journal-title":"N Engl J Med"},{"issue":"6","key":"4833_CR4","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M et al (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76(6):960\u2013977","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"4833_CR5","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/art.39953","volume":"69","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M et al (2017) Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheum 69(3):506\u2013517","journal-title":"Arthritis Rheum"},{"issue":"10","key":"4833_CR6","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1007\/s10067-018-4199-7","volume":"37","author":"S Kunwar","year":"2018","unstructured":"Kunwar S, Collins CE, Constantinescu F (2018) Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials. Clin Rheumatol 37(10):2611\u20132620","journal-title":"Clin Rheumatol"},{"issue":"2","key":"4833_CR7","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s10067-018-4299-4","volume":"38","author":"F Huang","year":"2019","unstructured":"Huang F, Luo ZC (2019) Adverse drug events associated with 5mg versus 10mg tofacitinib (Janus kinase inhibitor) twice daily for the treatment of autoimmune diseases: a systematic review and meta-analysis of randomized controlled trials. Clin Rheumatol 38(2):523\u2013534","journal-title":"Clin Rheumatol"},{"issue":"1","key":"4833_CR8","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","volume":"76","author":"M Dougados","year":"2017","unstructured":"Dougados M, van der Heijde D, Chen YC, Greenwald M, Drescher E, Liu J, Beattie S, Witt S, de la Torre I, Gaich C, Rooney T, Schlichting D, de Bono S, Emery P (2017) Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis 76(1):88\u201395","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4833_CR9","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1093\/rheumatology\/kez002","volume":"58","author":"EH Choy","year":"2019","unstructured":"Choy EH (2019) Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology (Oxford) 58(6):1122","journal-title":"Rheumatology (Oxford)"},{"key":"4833_CR10","first-page":"734","volume":"78","author":"K Queeney","year":"2019","unstructured":"Queeney K, Housley W, Sokolov J, Long A (2019) FRI0131 elucidating the mechanism underlying creatine phosphokinase upregulation with updacitinib. Ann Rheum Dis 78:734\u2013735","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04833-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-019-04833-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04833-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T00:50:09Z","timestamp":1606438209000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-019-04833-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,28]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["4833"],"URL":"https:\/\/doi.org\/10.1007\/s10067-019-04833-6","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,28]]},"assertion":[{"value":"14 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}